In 2019, many innovative findings were published that will be highly relevant for neuroprotection research in movement disorders. Substantial contributions from basic science have provided a better understanding of the propagation of α-synuclein, which has driven research into new therapies, such as the ongoing trials with antibodies against aggregated α-synuclein. Clinical trials using new therapies for Huntington's disease with antisense oligonucleotides have also reported promising results. Trials of the mainstay treatment for Parkinson's disease, levodopa, showed that this drug was only effective for symptomatic relief and had no disease-modifying effects. However, the discovery that levodopa metabolism is influenced by bacteria in the small intestine has brought up a new perspective on the effective doses of this drug. ^, 

中文翻译：

---

2019年的运动障碍：从抗体到生活方式干预。

在2019年，发表了许多创新性发现，这些发现与运动障碍的神经保护研究高度相关。基础科学的实质性贡献使人们对α-突触核蛋白的传播有了更好的了解，从而推动了对新疗法的研究，例如正在进行的针对聚集的α-突触核蛋白抗体的试验。使用针对亨廷顿氏病的新疗法和反义寡核苷酸的临床试验也报告了令人鼓舞的结果。帕金森氏病左旋多巴的主要治疗方法的试验表明，该药仅对缓解症状有效，对疾病没有改善作用。然而，左旋多巴代谢受小肠细菌影响的发现为该药物的有效剂量带来了新的认识。^，